×
About 530 results

ALLMedicine™ Multicentric Castleman Disease Center

Research & Reviews  199 results

Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis
https://clinicaltrials.gov/ct2/show/NCT04742387

May 20th, 2022 - Title: Assessment of Bone Mineral Density in People Living with HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis Study Description: This is a retrospective review that includes all participants with human immunodeficienc...

History of the KSHV Inflammatory Cytokine Syndrome (KICS)
https://clinicaltrials.gov/ct2/show/NCT01419561

May 20th, 2022 - BACKGROUND: KSHV inflammatory cytokine syndrome (KICS) is a newly recognized syndrome caused by Kaposi sarcoma-associated herpesvirus (KSHV). It is characterized by severe inflammatory symptoms including fevers, wasting, cytopenias, hypoalbuminemi...

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT02659930

May 20th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor that most frequently involves skin, but can also involve lymph nodes, lungs and gastrointestinal tract. It is most common in people with HIV or other forms of immune compro...

The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE ...
https://doi.org/10.1111/bjh.18214
British Journal of Haematology; Fajgenbaum DC, Pierson SK et. al.

May 5th, 2022 - Castleman disease (CD) describes a group of rare, potentially fatal lymphoproliferative disorders. To determine factors associated with mortality in CD, we analysed data from deceased patients in the ACCELERATE registry and compared them with matc...

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
https://clinicaltrials.gov/ct2/show/NCT03933904

Apr 22nd, 2022 - Human herpesvirus(HHV)-8-negative, idiopathic multicentric Castleman disease (iMCD) is a rare hematologic illness. Current therapeutic options are limited and provide benefit for only a subset of patients. Blockade of IL-6 signaling with siltuxima...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  5 results

Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis
https://clinicaltrials.gov/ct2/show/NCT04742387

May 20th, 2022 - Title: Assessment of Bone Mineral Density in People Living with HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis Study Description: This is a retrospective review that includes all participants with human immunodeficienc...

History of the KSHV Inflammatory Cytokine Syndrome (KICS)
https://clinicaltrials.gov/ct2/show/NCT01419561

May 20th, 2022 - BACKGROUND: KSHV inflammatory cytokine syndrome (KICS) is a newly recognized syndrome caused by Kaposi sarcoma-associated herpesvirus (KSHV). It is characterized by severe inflammatory symptoms including fevers, wasting, cytopenias, hypoalbuminemi...

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT02659930

May 20th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor that most frequently involves skin, but can also involve lymph nodes, lungs and gastrointestinal tract. It is most common in people with HIV or other forms of immune compro...

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
https://clinicaltrials.gov/ct2/show/NCT03933904

Apr 22nd, 2022 - Human herpesvirus(HHV)-8-negative, idiopathic multicentric Castleman disease (iMCD) is a rare hematologic illness. Current therapeutic options are limited and provide benefit for only a subset of patients. Blockade of IL-6 signaling with siltuxima...

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
https://clinicaltrials.gov/ct2/show/NCT04838860

Apr 19th, 2021 - This is an open-label, two-stage, Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD who progressed with elevated and rising serum C reactive protein (CRP) levels a...

see more →

News  5 results

Doxorubicin-pomalidomide combo shows promise for Kaposi sarcoma
https://www.mdedge.com/infectiousdisease/article/237118/hiv/doxorubicin-pomalidomide-combo-shows-promise-kaposi-sarcoma
Caleb Rans, PharmD

Mar 12th, 2021 - Liposomal doxorubicin (Dox) plus pomalidomide (Pom) was safe and active in heavily pretreated patients with Kaposi sarcoma, according to results from a phase 1/2 trial. Dr.

Teaching an Old Dog New Tricks: Repurposing Cancer Drugs to Combat COVID-19
https://www.onclive.com/view/teaching-an-old-dog-new-tricks-repurposing-cancer-drugs-to-combat-covid-19

Feb 5th, 2021 - In response to the novel coronavirus disease 2019 (COVID-19) pandemic, investigators around the world channeled their efforts into acquiring a better understanding of the virus so that they could rapidly identify any weapons that may be used in th...

New guidelines for idiopathic multicentric Castleman disease
https://www.mdedge.com/hematology-oncology/article/184660/related-issues/new-guidelines-idiopathic-multicentric-castleman-disease
Andrew D. Bowser

Oct 10th, 2018 - Photo from Penn Medicine David C. Fajgenbaum, MD The anti-IL-6 antibody siltuximab is central to first-line treatment of idiopathic multicentric Castleman disease (iMCD), according to new guidelines on iMCD published in Blood.

OncoBreak: Better Mammography; Fuel for Cancer Cells; Patients Need More Info
https://www.medpagetoday.com/hematologyoncology/breastcancer/63366

Feb 23rd, 2017 - Use of breast tomosynthesis with digital mammography significantly reduced the number of women recalled for additional tests. (RSNA, Radiology) The College of American Pathologists and American Society of Hematology issued new guideline for the in...

Valganciclovir Cut Oral Shedding of Herpesvirus 8
https://www.mdedge.com/internalmedicine/article/12699/infectious-diseases/valganciclovir-cut-oral-shedding-herpesvirus-8
Sherry Boschert

SAN FRANCISCO — The first randomized, controlled clinical study of an antiviral medication's effects on human herpesvirus 8 found a 79% reduction in viral shedding in the oropharynx of 26 men taking 900 mg/day of valganciclovir, Dr. Corey Casper r.

see more →

Patient Education  2 results see all →